Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2013-10-28

Clinical Trial Update: Malignancy Meta Analysis for BRL49653

View source ↗

Summary

Clinical trial update presenting a meta-analysis of malignancy risk for BRL49653 in Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BRL49653

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED